$PBLS

RA CAPITAL MANAGEMENT, L.P. purchased $6.9M of PBLS (indirect holdings)

RA CAPITAL MANAGEMENT, L.P. purchased 244,593 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $28.29 ($27.13–$30.00, $6.92M total) across 6 trades over 2026-07-20 to 2026-07-22.

Original reporting
SEC EDGAR · RA CAPITAL MANAGEMENT, L.P.
Published Jul 22, 2026, 8:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 22, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PBLS
Bullish
medium confidence
Mentioned
$PBLS
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PBLSBullishLow
01

Why it matters

A large shareholder (RA Capital Management, L.P.) reported open-market purchases totaling about $6.92M over several days, with no 10b5-1 plan cited.

02

Market read

Traders may treat the filing as a modest sentiment input, but it does not provide new operational or valuation-driving information.

03

What to watch

Indirect holdings and multiple small lots can reduce interpretability; without accompanying company news, price reaction may fade quickly.

Relevance 7/10Novelty 5/10Timing: Filed 2026-07-22 after trades on 2026-07-20 to 2026-07-22.

Background

The article is an SEC Form 4 insider transaction disclosure for Parabilis Medicines, Inc. (PBLS).

Company-level read

Ticker impact

$PBLSBullishMedium confidence
Context

RA Capital Management, a 10% owner, bought $6.92M of PBLS shares via open-market purchases from 2026-07-20 to 2026-07-22.

Expected impact

Near-term impact likely limited, with any effect more sentiment-driven than fundamental.

Evidence & confidence

Form 4 shows purchase size and timing, yet it does not disclose new company-specific operating information; 10b5-1 was not used, which can increase interpretive weight but still lacks a direct business update.

Market effects

Limited sector read-through; this is company-specific insider/holder activity rather than a sector-wide signal.

None indicated.

None indicated.

Counterpoint

The purchase could reflect portfolio rebalancing or liquidity needs rather than a bullish view on near-term fundamentals.

Key entities

  • Parabilis Medicines, Inc.

    Company whose shares were purchased; Form 4 reports the transaction details.

  • RA Capital Management, L.P.

    Reporter of the Form 4 purchase activity in PBLS shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PBLSMed

Parabilis Medicines, Inc. (PBLS): Results of Operations and Financial Condition

Parabilis Medicines, Inc. (PBLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates Advanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research colla

$PBLSMed

Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch

Biotech stocks rose on varied catalysts. Parabilis (PBLS) debuted on Nasdaq, up 58% to $31.60 after pricing a $20.00 IPO of 33.5M shares for ~$670M gross proceeds. Clover Health (CLOV) gained 14% to $4.89 after a court ruling upgraded its 2026 PPO Star Rating to 4.5 from 3.5. Myomo (MYO) rose 17% to $1.54; Shoulder Innovations (SI) up 17% to $17.89; GMRS up 13% to $13.18.

$PBLSMedAI 9/10

Parabilis Medicines raises record $670 million in biotech IPO

Parabilis Medicines priced its Nasdaq IPO at $20/share, raising $670 million by selling 33.5 million shares, above its $17–$19 range, according to the company. Trading under “PBLS” starts Wednesday. Underwriters can buy 5.025 million more shares. A related private placement with Regeneron bought 4.17 million shares at $18, adding ~$75 million. Total raised is ~$745 million; valuation is ~$2.4 billion.